Table II.
The relationship between the GAS5 expression and the clinicopathological factors in ovarian cancer patients.
| Clinical parameter | miR-221
|
Chi-squared test P-value | |
|---|---|---|---|
| Group 1 | Group 2 | ||
| Age (years) | 0.8052 | ||
| <55 | 14 | 15 | |
| >55 | 18 | 16 | |
| Size (cm) | 0.0010 | ||
| >5 | 9 | 24 | |
| <5 | 21 | 9 | |
| Histologic differentiation | 0.9463 | ||
| Well | 3 | 2 | |
| Moderate | 11 | 12 | |
| Poor | 14 | 14 | |
| Undifferentiated | 4 | 3 | |
| Invasion depth | 0.0003 | ||
| T1 | 10 | 5 | |
| T2 | 13 | 3 | |
| T3 | 4 | 14 | |
| T4 | 3 | 12 | |
| FIGO stages | 0.0076 | ||
| I | 6 | 2 | |
| II | 15 | 7 | |
| III | 8 | 19 | |
| IV | 1 | 5 | |
| Lymphatic metastasis | 0.4985 | ||
| Yes | 18 | 12 | |
| No | 17 | 16 | |
| Distant metastasis | 0.6723 | ||
| Yes | 3 | 5 | |
| No | 25 | 30 | |